SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma - Quaterly Results

28 Jul 2022 Evaluate
The revenue for the June 2022 quarter is pegged at Rs. 8502.90 millions, about 14.48% up against Rs. 7427.20 millions recorded during the year-ago period.The Net proft of the company remain more or less same to Rs. 1503.70  millions from Rs. 1934.60 millions ,decline by -22.27%.Operating profit for the quarter ended June 2022 decreased to 2217.30 millions as compared to 2640.20 millions of corresponding quarter ended June 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 8502.90 7427.20 14.48 8502.90 7427.20 14.48 31406.40 27185.90 15.52
Other Income 354.20 310.00 14.26 354.20 310.00 14.26 1397.30 1035.70 34.91
PBIDT 2217.30 2640.20 -16.02 2217.30 2640.20 -16.02 10306.20 10204.80 0.99
Interest 6.30 11.70 -46.15 6.30 11.70 -46.15 91.20 69.00 32.17
PBDT 2211.00 2628.50 -15.88 2211.00 2628.50 -15.88 10215.00 10135.80 0.78
Depreciation 307.50 297.60 3.33 307.50 297.60 3.33 1209.60 1114.90 8.49
PBT 1903.50 2330.90 -18.34 1903.50 2330.90 -18.34 9005.40 9020.90 -0.17
TAX 399.80 396.30 0.88 399.80 396.30 0.88 1806.80 2264.50 -20.21
Deferred Tax -18.30 32.60 -156.13 -18.30 32.60 -156.13 95.10 97.70 -2.66
PAT 1503.70 1934.60 -22.27 1503.70 1934.60 -22.27 7198.60 6756.40 6.54
Equity 257.10 173.90 47.84 257.10 173.90 47.84 171.70 173.90 -1.27
PBIDTM(%) 26.08 35.55 -26.64 26.08 35.55 -26.64 32.82 37.54 -12.58

Ajanta Pharma Share Price

2790.15 -37.95 (-1.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×